在静息和负荷成像期间，使用全氟丙烷微球对比超声心动图的安全性特征：来自澳大利亚多中心队列的研究结果。

The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort.

机构信息

Echocardiography Department, The Prince Charles Hospital, Australia; School of Medicine, University of Queensland, Australia.

出版信息

Heart Lung Circ. 2013 Dec;22(12):996-1002. doi: 10.1016/j.hlc.2013.05.637. Epub 2013 Jun 10.

DOI:10.1016/j.hlc.2013.05.637

PMID:23764145

Abstract

BACKGROUND

Contrast enhanced echocardiography (CEE) is utilised when sub-optimal image quality results in non-diagnostic echocardiograms. However, there have been numerous safety notices issued by regulatory authorities regarding rare but potentially serious adverse reactions (AR). This multi-centre, retrospective analysis was performed to assess the short-term safety of CEE in a broad range of indications.

METHODS

All CEE performed over 58 months at three institutions were assessed for AR within 30 min.

RESULTS

A total of 5956 CEE were performed in 5576 patients. A total of 4903 were stress CEE and 1053 resting CCE. Bolus administration in 5719, infusion in 237 cases; 89.9% of CCE were outpatients. Commonest CEE indication was functional stress testing (82.3%). There were 16 AR related to CEE (0.27%). All AR were mild, transient and all patients made a full recovery. No cases of serious anaphylaxis or death within 30 min of contrast administration. Comparing those with and without an AR, there were no significant differences in age, gender, BMI, LVEF, patient location, exam type or RVSP. There was a slightly increased likelihood of an AR during infusion versus bolus dosing (p = 0.02).

CONCLUSION

CEE is a safe investigation in a broad range of indications and clinical scenarios. AR are very rare, mild and transient.

摘要

背景

当超声心动图图像质量不佳导致诊断不明确时，会使用对比增强超声心动图（CEE）。然而，监管机构已经发布了许多关于罕见但潜在严重不良反应（AR）的安全通知。这项多中心、回顾性分析旨在评估广泛适应证下 CEE 的短期安全性。

方法

在三个机构的 58 个月内，对所有进行的 CEE 进行了 30 分钟内的 AR 评估。

结果

共进行了 5956 例 CEE，涉及 5576 例患者。共有 4903 例为应激 CEE，1053 例为静息 CCE。在 5719 例中进行了推注给药，在 237 例中进行了输注给药；89.9%的 CCE 为门诊患者。最常见的 CEE 适应证是功能应激测试（82.3%）。共有 16 例与 CEE 相关的 AR（0.27%）。所有 AR 均为轻度、短暂，所有患者均完全康复。在对比剂给药后 30 分钟内，无严重过敏反应或死亡病例。比较有 AR 和无 AR 的患者，在年龄、性别、BMI、LVEF、患者位置、检查类型或 RVSP 方面无显著差异。与推注给药相比，输注给药时发生 AR 的可能性略有增加（p=0.02）。